sunitinib
Showing 1 - 25 of 179
Refractory Solid Tumors Trial in Seoul (Sunitinib)
Completed
- Refractory Solid Tumors
- Sunitinib
-
Seoul, Seoul, Korea, Republic Of, Korea, Republic ofSamsung Medical Center
Jun 13, 2022
Gastrointestinal Stromal Tumors Trial in Miami (Sunitinib, Regorafenib)
Recruiting
- Gastrointestinal Stromal Tumors
- Sunitinib
- Regorafenib
-
Miami, FloridaUniversity of Miami
Jul 28, 2022
Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer Trial in United States (CGT9486 plus sunitinib, CGT9486, Sunitinib)
Recruiting
- Advanced Gastrointestinal Stromal Tumors
- Metastatic Cancer
- CGT9486 plus sunitinib
- +2 more
-
Duarte, California
- +11 more
Aug 10, 2022
Renal Cell Carcinoma Trial (Pembrolizumab, Axitinib, Sunitinib)
Active, not recruiting
- Renal Cell Carcinoma
- Pembrolizumab
- +2 more
- (no location specified)
Aug 17, 2022
Real-world Clinical Patterns Of Care And Outcomes Among AfME
Recruiting
- Metastatic Renal Cell Carcinoma
- Sunitinib
-
Algers, Algeria
- +5 more
Aug 16, 2022
Metastatic and/or Advanced Renal Cell Carcinoma, Treated With
Paraganglioma, Pheochromocytoma Trial in Canada, Netherlands (Sunitinib)
Active, not recruiting
- Paraganglioma
- Pheochromocytoma
- Sunitinib
-
Calgary, Alberta, Canada
- +3 more
Nov 29, 2021
Brain Metastases Trial in Toronto (Sunitinib)
Active, not recruiting
- Brain Metastases
- Sunitinib
-
Toronto, Ontario, CanadaUniversity Health Network, Princess Margaret Hospital
Oct 4, 2021
Kidney Tumors, Metastatic Renal Cell Cancer Trial in Besancon (Sunitinib)
Active, not recruiting
- Kidney Neoplasms
- Metastatic Renal Cell Cancer
- Sunitinib
-
Besancon, Franche-Comté, FranceCHU Besancon
Nov 17, 2021
Clear-cell Renal Cell Carcinoma, RCC, Kidney Cancer Trial in Birmingham (Avelumab, Sunitinib)
Withdrawn
- Clear-cell Renal Cell Carcinoma
- +3 more
- Avelumab
- Sunitinib
-
Birmingham, AlabamaUniversity of Alabama Hematology Oncology Clinic at Medical West
Feb 14, 2022
Renal Cell Carcinoma Metastatic Trial in Hershey (Abemaciclib, Sunitinib)
Active, not recruiting
- Renal Cell Carcinoma Metastatic
- Abemaciclib
- Sunitinib
-
Hershey, PennsylvaniaPenn State Cancer Institute
Jan 5, 2022
CR With Sunitinib Treatment In mRCC Patients
Completed
- Complete Remission in Renal Cell Carcinoma
- sunitinib
-
Marseille, Cedex 5, France
- +13 more
Feb 14, 2022
Non GIST Sarcomas Trial in France (sunitinib)
Completed
- Non GIST Sarcomas
- sunitinib
-
Bordeaux, France
- +5 more
Jan 3, 2022
Type B3 Thymoma, Thymic Carcinoma Trial in Milan (Sunitinib)
Recruiting
- Type B3 Thymoma
- Thymic Carcinoma
- Sunitinib
-
Milan, ItalyNational Cancer Institute
Jun 8, 2021
Renal Cell Carcinoma, Metastatic Trial in Worldwide (Intuvax (INN: ilixadencel), Sunitinib)
Completed
- Renal Cell Carcinoma, Metastatic
- Intuvax (INN: ilixadencel)
- Sunitinib
-
Chicago, Illinois
- +27 more
Jul 23, 2022
Kidney Cancer Trial in Boston, Houston, Salt Lake City (Everolimus, Sunitinib)
Carcinoma, Renal Cell Trial in Durham (Sunitinib)
Completed
- Carcinoma, Renal Cell
- Sunitinib
-
Durham, North CarolinaDuke Cancer Institute
Nov 23, 2020
Small Cell Lung Cancer Trial in United States (irinotecan, Carboplatin, sunitinib)
Metastatic Renal Cell Carcinoma Who Received Sunitinib After 1st
Completed
- Metastatic Renal Cell Carcinoma (mRCC)
- sunitinib
-
Calgary, Alberta, CanadaUniversity of Calgary
Mar 8, 2021
Sunitinib Treatment on Tissue Sodium Accumulation (TSS2)
Completed
- Renal Cell Cancer Metastatic
- +2 more
- Sunitinib
-
Berlin, GermanyExperimental and Clinical Research Center, Clinical Research Uni
Jan 25, 2021
Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma Trial in Canada, United States (Nivolumab, Pazopanib,
Completed
- Renal Cell Carcinoma
- Clear-cell Metastatic Renal Cell Carcinoma
- Nivolumab
- +3 more
-
Duarte, California
- +13 more
Nov 30, 2021
Renal Cell Carcinoma Who Received First-Line Sunitinib
Completed
- Metastatic Renal Cell Carcinoma
- Sunitinib
-
Calgary, Alberta, CanadaUniversity of Calgary
Feb 19, 2021
Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1 Trial in
Recruiting
- Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1
- Biological : Toripalimab Drug: Axitinib
- sunitinib
-
Beijing, ChinaBeijing Cancer Hospital
Jan 24, 2021
Carcinoma, Renal Cell Trial in China, Korea, Republic of, Taiwan (Pazopanib, Sunitinib)
Completed
- Carcinoma, Renal Cell
- Pazopanib
- Sunitinib
-
Guangzhou, Guangdong, China
- +20 more
Dec 6, 2021